This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Why Ariad Pharmaceuticals (ARIA) is Soaring

NEW YORK (TheStreet) -- Ariad Pharmaceuticals (ARIA) is up, up, and away, after good news on Friday had the stock extending its rally through to Monday. Over the last two trading days, the stock has soared 82.4%.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday ruled that Ariad could continue marketing leukemia drug Iclusig, albeit with restrictions in place. These restrictions include advising against use in patients with a history of heart attack or stroke. Nonetheless, the decision bolsters Ariad's outlook.

By early afternoon Monday, the pharmaceuticals company had gained 33.6% to $5.05, and 45.15 million shares had changed hands, well over the three-month average daily trading volume of 18.6 million.

Also boosting shares, BMO Capital Markets reiterated a "market perform" rating and upgraded its 12-month price target to $4 from $2.50. However, the investment firm notes the CHMP decision doesn't necessarily mean a positive assessment by the FDA in the U.S.

Shares crashed 88% over October after Iclusig was suspended in the U.S. following studies showing an increase in blood clots and heart issues among medicated patients. In a statement, Ariad said the Iclusig marketing halt was a temporary measure while it "continues to negotiate updates to the U.S. prescribing information".

--Written by Keris Alison Lahiff.

For fun: The 10 Drunkest States in America... and the 10 most sober

Stock quotes in this article: ARIA 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs